Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
Elsa Bernard(Inserm), Alexandra Smith(Yorkshire Cancer Research), Lionel Adès(Délégation Paris 7), Max F. Levine(Memorial Sloan Kettering Cancer Center), Martin Jädersten(Karolinska University Hospital), Julie Schanz(Universitätsmedizin Göttingen), Arjan A. van de Loosdrecht(Dutch Cancer Society), Ιoannis Kotsianidis(Democritus University of Thrace), Takayuki Ishikawa(Kobe City Medical Center General Hospital), Olivier Kosmider(Centre National de la Recherche Scientifique), Akifumi Takaori‐Kondo(Kyoto University), Robert P. Hasserjian(Massachusetts General Hospital), Toru Kiguchi(Chugoku Central Hospital), Hisashi Tsurumi(Matsunami General Hospital), Matilde Y. Follo(University of Bologna), Ryunosuke Saiki(Kyoto University), Yusuke Shiozawa(Atrium Health Wake Forest Baptist), Jacqueline Boultwood(University of Oxford), Juan S. Medina-Martínez(Memorial Sloan Kettering Cancer Center), Sean M. Devlin(Memorial Sloan Kettering Cancer Center), Virginia M. Klimek(Memorial Sloan Kettering Cancer Center), Ronald Feitosa Pinheiro(Universidade Federal do Ceará), Michael R. Savona(Vanderbilt University), Guillermo Sanz(Instituto de Salud Carlos III), Felicitas Thol(Medizinische Hochschule Hannover), Monika Beličková(Institute of Haematology and Blood Transfusion), Juan E. Arango(Memorial Sloan Kettering Cancer Center), Senji Kasahara(Gifu Municipal Hospital), Ulrich Germing(Düsseldorf University Hospital), John M. Bennett(University of Rochester Medical Center), Yasuhito Nannya(Kyoto University), Heinz Tuechler, Luca Malcovati(Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán), Tetsuichi Yoshizato(Kyoto University), Catherine Cargo(St James's University Hospital), Christina Ganster(Universitätsmedizin Göttingen), Françesc Solé(Fundación Josep Carreras Contra la Leucemia), Chantana Polprasert(Chulalongkorn University), Magnus Tobiasson(Karolinska University Hospital), Gunes Gundem(Memorial Sloan Kettering Cancer Center), Harold K. Elias(Memorial Sloan Kettering Cancer Center), Fábio Pires de Souza Santos(Hospital Israelita Albert Einstein), Laura Palomo(Fundación Josep Carreras Contra la Leucemia), Matteo Giovanni Della Porta(Humanitas University), Valeria Santini(Azienda Ospedaliero-Universitaria Careggi), Detlef Haase(Universitätsmedizin Göttingen), Yangyu Zhou(Memorial Sloan Kettering Cancer Center), Maria Creignou(Karolinska University Hospital), Yanming Zhang(Memorial Sloan Kettering Cancer Center), Araxe Sarian(Memorial Sloan Kettering Cancer Center)
Cited by 633
Related Papers
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3k
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
|Journal of Clinical Oncology|2003|2.7k